HPV vaccination for the prevention of cervical intraepithelial neoplasia

New England Journal of Medicine

Volumn 361, Issue 3, 2009, Pages 271-

  Kahn, Jessica A ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SILGARD; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

ADULT; ARTICLE; CANCER PREVENTION; CASE REPORT; CLINICAL EXAMINATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; ELECTROSURGERY; ERYTHEMA; FAMILY HISTORY; FATIGUE; FEMALE; FEVER; GUILLAIN BARRE SYNDROME; HEADACHE; HUMAN; HUMAN TISSUE; INJECTION SITE PAIN; INJECTION SITE SWELLING; MOTHER; MYALGIA; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SEXUAL BEHAVIOR; SYNCOPE; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; VENOUS THROMBOEMBOLISM; VIRUS INFECTION;

EID: 67650876227     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMct0806938     Document Type: Article

References (61)

1. Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection among females in the United States. JAMA 2007;297:813-9.
2. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997;102:3-8.
3. Winer RL, Feng Q, Hughes JP, O'Reilly S, Kiviat NB, Koutsky LA. Risk of female human papillomavirus acquisition associated with first male sex partner. J Infect Dis 2008;197:279-82.
4. WHO/ICO Information Centre on HPV and Cervical Cancer. HPV and cervical cancer in the world: 2007 report. Vaccine 2007;25:Suppl 3:C1-C230.
5. Horner MJ, Ries LAG, Krapcho M, et al., eds. SEER Cancer Statistics Review, 1975-2006. Bethesda, MD: National Cancer Institute. (Accessed June 22, 2009, at http://seer.cancer.gov/csr/1975-2006.)
6. Insinga RP, Dasbach EJ, Elbasha EH. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature. Pharmacoeconomics 2005;23:1107-22.
7. Insinga RP. Annual productivity costs due to cervical cancer mortality in the United States. Womens Health Issues 2006;16:236-42.
8. Muñoz N, Castellsagué X, de González AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006;24:Suppl 3:S3/1-S3/10.
9. Stanley M. Immunobiology of HPV and HPV vaccines. Gynecol Oncol 2008;109:Suppl:S15-S21.
10. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002;2:342-50.
11. Bergler WF, Götte K. Current advances in the basic research and clinical management of juvenile-onset recurrent respiratory papillomatosis. Eur Arch Otorhinolaryngol 2000;257:263-9.
12. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244-65.
13. Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine 2006;24:Suppl 3:S3/11-S3/25.
14. Insinga RP, Liaw KL, Johnson LG, Madeleine MM. A systematic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal, and vulvar precancers and cancers in the United States. Cancer Epidemiol Biomarkers Prev 2008;17:1611-22.
15. Muñoz N, Bosch FX, de Sanjosé S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27.
16. Clifford GM, Smith JS, Plummer M, Muñoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003;88:63-73.
17. Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007;121:621-32.
18. Frazer IH. Prevention of cervical cancer through papillomavirus vaccination. Nat Rev Immunol 2004;4:46-54.
19. Boulet G, Horvath C, Vanden Broeck D, Sahebali S, Bogers J. Human papillomavirus: E6 and E7 oncogenes. Int J Biochem Cell Biol 2007;39:2006-11.
20. Wheeler CM. Natural history of human papillomavirus infections, cytologic and histologic abnormalities, and cancer. Obstet Gynecol Clin North Am 2008;35: 519-36.
21. Stoler MH. The virology of cervical neoplasia: an HPV-associated malignancy. Cancer J 2003;9:360-7.
22. Block SL, Nolan T, Sattler C, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006;118:2135-45.
23. Garland SM, Hernandez-Avila M, Wheeler CM. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928-43.
24. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007;369:2161-70. [Erratum, Lancet 2007;370:1414.]
25. Reisinger KS, Block SL, Lazcano-Ponce E, et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J 2007;26:201-9.
26. Olsson SE, Villa LL, Costa RL, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 2007;25:4931-9.
27. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006;367:1247-55.
28. Lehtinen M, Herrero R, Mayaud P, et al. Chapter 28: Studies to assess the longterm efficacy and effectiveness of HPV vaccination in developed and developing countries. Vaccine 2006;24:Suppl 3:S3/233-S241.
29. The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-27.
30. Joura EA, Leodolter S, Hernandez-Avila M, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007;369:1693-702.
31. Harper D, Gall S, Naud P, et al. Sustained immunogenicity and high efficacy against HPV-16/18 related cervical neoplasia: long-term follow up through 6.4 years in women vaccinated with Cervarix. Presented at the 39th annual meeting of the Society of Gynecologic Oncologists, Tampa, FL, March 9-12, 2008. abstract.
32. Brown DR, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naïve women aged 16-26 years. J Infect Dis 2009;199:926-35.
33. Product approval information: human papillomavirus quadrivalent (types 6, 11, 16, 18) vaccine, recombinant. Silver Spring, MD: Food and Drug Administration, 2008. (Accessed June 22, 2009, at http://www.fda.gov/cber/ products/gardasil.htm.)
34. Eaton DK, Kann L, Kinchen S, et al. Youth risk behavior surveillance - United States, 2005. MMWR Surveill Summ 2006;55:1-108.
35. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007;56(RR-2):1-24.
36. Wright TC Jr, Huh WK, Monk BJ, Smith JS, Ault K, Herzog TJ. Age considerations when vaccinating against HPV. Gynecol Oncol 2008;109:Suppl:S40- S47.
37. Winer RL, Hughes JP, Feng Q, et al. Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med 2006;354:2645-54.
38. Saslow D, Runowicz C, Solomon D, et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 2002;52:342-62.
39. 2009 Child and adolescent immunization schedules. Atlanta: Centers for Disease Control and Prevention. (Accessed June 22, 2009, at http://www.cdc.gov/ vaccines/recs/schedules/child-schedule.htm.)
40. Wheeler CM, Bautista OM, Tomassini JE, Nelson M, Sattler CA, Barr E. Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines. Vaccine 2008;26:686-96.
41. American Academy of Pediatrics Committee on Infectious Diseases. Prevention of human papillomavirus infection: provisional recommendations for immunization of girls and women with quadrivalent human papillomavirus vaccine. Pediatrics 2007;120:666-8.
42. Summary tables of cervical cancer screening guidelines and recommendations for new technologies. Atlanta: Centers for Disease Control and Prevention. (Accessed June 22, 2009, at http://www.cdc.gov/std/hpv/ ScreeningTables.pdf.)
43. HPV vaccine information for young women. Atlanta: Centers for Disease Control and Prevention. (Accessed June 22, 2009, at http://www.cdc.gov/std/hpv/ STDFact-HPV-vaccine-young-omen.htm.)
44. HPV vaccine: implementation and financing policy in the U.S. Washington, DC: Henry J. Kaiser Family Foundation, 2008. (Accessed June 22, 2009, at http://www.kff.org/womenshealth/upload/7602-02.pdf.)
45. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 viruslike particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6:271-8.
46. Reports of health concerns following HPV vaccination. Atlanta: Centers for Disease Control and Prevention. (Accessed June 22, 2009, at http://www.cdc.gov/vaccinesafety/vaers/gardasil.htm.)
47. Giuliano AR, Palefsky JM. The efficacy of quadrivalent HPV (types 6/11/16/18) vaccine in reducing the incidence of HPV infection and HPV-related genital disease in young men. Presented at the EUROGIN [European Research Organization on Genital Infection] International Multidisciplinary Conference, Nice, France, November 12-15, 2008. abstract.
48. Kim JJ, Andres-Beck B, Goldie SJ. The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting. Br J Cancer 2007;97:1322-8.
49. Barnabas RV, Laukkanen P, Koskela P, Kontula O, Lehtinen M, Garnett GP. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modeling analyses. PLoS Med 2006;3(5):e138.
50. Schwarz TF, Dubin GO. An AS04-containing human papillomavirus (HPV) 16/18 vaccine for prevention of cervical cancer is immunogenic and well-tolerated in women 15-55 years old. Proc Am Soc Clin Oncol 2006;24:1008. abstract.
51. Luna J, Saah AJ, Hood S, Bautista OM, Barr E. Safety, efficacy, and immunogenicity of quadrivalent HPV vaccine (Gardasil) in women aged 24-45. Presented at the 24th International Papillomavirus Conference, Beijing, November 3-9 2007. abstract.
52. Palefsky JM, Gillison ML, Strickler HD. Chapter 16: HPV vaccines in immunocompromised women and men. Vaccine 2006;24:Suppl 3:S3/140-S3/146.
53. Myers E, Huh WK, Wright JD, Smith JS. The current and future role of screening in the era of HPV vaccination. Gynecol Oncol 2008;109:2 Suppl:S31-S39.
54. Kiviat NB, Hawes SE, Feng Q. Screening for cervical cancer in the era of the HPV vaccine - the urgent need for both new screening guidelines and new biomarkers. J Natl Cancer Inst 2008;100:290-1.
55. Heideman DA, Snijders PJ, Berkhof J, Verheijen RH, Helmerhorst TJ, Meijer CJ. Vaccination against HPV: indications for women and the impact on the cervical screening programme. BJOG 2008;115:938-46.
56. Brewer NT, Cuite CL, Herrington JE, Weinstein ND. Risk compensation and vaccination: can getting vaccinated cause people to engage in risky behaviors? Ann Behav Med 2007;34:95-9.
57. Friedman LS, Kahn J, Middleman AB, Rosenthal SL, Zimet GD. Human papillomavirus (HPV) vaccine: a position statement of the Society for Adolescent Medicine. J Adolesc Health 2006;39:620.
58. Saslow D, Castle PE, Cox JT, et al. American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin 2007;57:7-28.
59. Koulova A, Tsui J, Irwin K, Van Damme P, Biellik R, Aguado MT. Country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries, June 2006-January 2008. Vaccine 2008;26:6529-41.
60. Human papillomavirus vaccines: WHO position paper. Wkly Epidemiol Rec 2009;84:118-31.
61. Kollar LM, Kahn JA. Education about human papillomavirus and human papillomavirus vaccines in adolescents. Curr Opin Obstet Gynecol 2008;20:479-83.